Skip to content

Merck & Co. MRK Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Zoetis logo
ZoetisZTS
Summit Therapeutics logo
Summit TherapeuticsSMMT
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
Arcus Biosciences logo
Arcus BiosciencesRCUS

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total equity$45.9B-5.1%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$317.37B+61.7%
Enterprise value$361.07B+60.4%
P/E35.5×+23.6×
P/S4.8×+1.7×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp
FCF margin21.5%-5.2pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s common stock, shares authorized (in shares)?
Merck & Co. (MRK) reported common stock, shares authorized (in shares) of 6.5B in Q1 2026.
How has Merck & Co.'s common stock, shares authorized (in shares) changed year-over-year?
Merck & Co.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from 6.5B to 6.5B.
What is the long-term trend for Merck & Co.'s common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Merck & Co.'s common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from 6.5B to 6.5B.